Compare DLPN & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | QTTB |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 44.3M |
| IPO Year | 2008 | 2018 |
| Metric | DLPN | QTTB |
|---|---|---|
| Price | $1.61 | $4.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 42.1K | ★ 145.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.81 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,684,984.00 | N/A |
| Revenue This Year | $10.62 | N/A |
| Revenue Next Year | $13.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 19.85 | ★ 100.00 |
| 52 Week Low | $0.75 | $1.38 |
| 52 Week High | $1.88 | $6.37 |
| Indicator | DLPN | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 63.67 |
| Support Level | $1.46 | $1.63 |
| Resistance Level | $1.73 | $6.37 |
| Average True Range (ATR) | 0.08 | 0.43 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 60.33 | 91.36 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.